- $150.21m
- -$195.64m
- 34
- 49
- 36
- 34
Annual balance sheet for BioAge Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Cash and Short Term Investments | 27.6 | 21.6 | 354 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 28 | 25.3 | 357 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.374 | 0.518 | 0.791 |
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | 28.4 | 25.9 | 358 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 5.86 | 58.2 | 27.8 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 8.27 | 66.6 | 35.1 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 20.2 | -40.7 | 323 |
| Total Liabilities & Shareholders' Equity | 28.4 | 25.9 | 358 |
| Total Common Shares Outstanding |